Xtant Medical Holdings, a global medical technology company focused on surgical solutions for the treatment of spinal, orthopaedic, and wound care disorders, announced the commercial launch of CollagenX™, its bovine collagen particulate product for surgical wound closure designed to promote healing, prevent dehiscence, and help mitigate concerns related to surgical site infections.

CollagenX is a potential addition to every case type currently addressed by Xtant’s biologics portfolio, as well as procedures performed in other surgical disciplines.